A new review and policy statement underscore the inaccuracy of sickle cell trait as a cause of death on autopsies.

The first Black graduate of The University of Texas at Austin, Oscar Thompson, studied zoology, as did trailblazing Longhorn ...

CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...

its gene-editing treatment for sickle cell disease and beta-thalassemia. Analysts responded positively to the results. According to The Fly, Barclays raised its price target on Vertex to $467 from ...

CRSP reports encouraging fourth-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is ...

Statistically significant means there is a very high likelihood the drug impacted its target. But if data are not clinically ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.

"This research provides crucial insights into how the immune system functions in sickle cell disease," said Dr. Karina Yazdanbakhsh, Vice President and Director of Research at New York Blood Center ...